LFA
UTHR icon

LGT Financial Advisors’s United Therapeutics UTHR Stock Holding History

LGT Financial Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-93
Closed -$32.8K – 708
2024
Q4 		$32.8K Hold
93
– – 0.07% 213
2024
Q3 		$33.3K Hold
93
– – 0.08% 184
2024
Q2 		$29.6K Hold
93
– – 0.06% 225
2024
Q1 		$21.4K Hold
93
– – 0.02% 350
2023
Q4 		$20.4K Hold
93
– – 0.03% 350
2023
Q3 		$21K Buy
+93
New +$21.4K 0.03% 329

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

LGT Financial Advisors's UTHR Position: Q1 2025 in Review

LGT Financial Advisors sold out of United Therapeutics (UTHR) in Q1 2025, closing a stake of 93 shares — an estimated $32.8K sold.

LGT Financial Advisors first reported a position in UTHR in Q3 2023 and held it in 6 quarters. The position peaked at $33.3K in Q3 2024. 673 funds tracked by Wall St. Rank hold UTHR as of Q1 2025.

  • LGT Financial Advisors reported no remaining United Therapeutics position as of Q1 2025 after selling out during the quarter.
  • LGT Financial Advisors sold 93 United Therapeutics shares in Q1 2025, an estimated $32.8K.
  • LGT Financial Advisors first reported a position in United Therapeutics in Q3 2023 and held it in 6 quarters.
  • LGT Financial Advisors's United Therapeutics position peaked at $33.3K in Q3 2024.
  • 673 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2025.

Based on LGT Financial Advisors's 13F filing for Q1 2025, filed 8 May 2025.